A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial

By Mercadante S.   Radbruch L.   Davies A.   Poulain P.   Sitte T.   Perkins P.   Colberg T.   Camba M.A.  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2805-2815

Informa Healthcare

Access to resources Recommend Favorite

Patient Satisfaction with Fentanyl Sublingual Spray in Opioid‐Tolerant Patients with Breakthrough Cancer Pain

By  

PAIN PRACTICE, Vol. 15, Iss. 6, 2015-07 ,pp. : 554-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fentanyl for Breakthrough Cancer Pain: Where are We?

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-03 ,pp. : 42-47

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain

By Rauck Richard L.   Tark Marvin   Reyes Eva   Hayes Teresa G.   Bartkowiak Anthony J.   Hassman David   Nalamachu Srinivas   Derrick Rob   Howell Julian  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2877-2885

Informa Healthcare

Access to resources Recommend Favorite

Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain

By ÜÜberall Michael A.   Müüller-Schwefe Gerhard H.H.  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1385-1394

Informa Healthcare

Access to resources Recommend Favorite